Kyle Dempsey
Director/Miembro de la Junta en OPTINOSE, INC. .
Fortuna: 6 089 $ al 30/04/2024
Cargos activos de Kyle Dempsey
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| OPTINOSE, INC. | Director/Miembro de la Junta | 10/12/2021 | - |
| Independent Dir/Board Member | 10/12/2021 | - | |
| HLS THERAPEUTICS INC. | Director/Miembro de la Junta | 29/11/2022 | - |
| Independent Dir/Board Member | 29/11/2022 | - | |
| MVM Partners LLC | Inversor de Capital Privado | 01/09/2017 | - |
GT Medical Technologies, Inc.
 GT Medical Technologies, Inc. Medical SpecialtiesHealth Technology GT Medical Technologies, Inc. engages in the design and development of a medical device for the treatment of brain tumors. It offers GammaTile Therapy, which is a surgically targeted radiation therapy which is placed at the end if a brain excision surgery and targets residual tumor cells. The company was founded by Heyoung McBride, Peter Nakaji, Emad Youssef, and Theresa Thomas in 2017 and is headquartered in Tempe, AZ. | Director/Miembro de la Junta | - | - |
Historial de carrera de Kyle Dempsey
Formación de Kyle Dempsey.
| Harvard Medical School | Doctorate Degree |
| Bowdoin College | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 7 |
| Canadá | 2 |
Operativa
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| Private Equity Investor | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 4 |
| Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| OPTINOSE, INC. | Health Technology |
| HLS THERAPEUTICS INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
| MVM Partners LLC | Finance |
GT Medical Technologies, Inc.
GT Medical Technologies, Inc. Medical SpecialtiesHealth Technology GT Medical Technologies, Inc. engages in the design and development of a medical device for the treatment of brain tumors. It offers GammaTile Therapy, which is a surgically targeted radiation therapy which is placed at the end if a brain excision surgery and targets residual tumor cells. The company was founded by Heyoung McBride, Peter Nakaji, Emad Youssef, and Theresa Thomas in 2017 and is headquartered in Tempe, AZ. | Health Technology |
- Bolsa de valores
- Insiders
- Kyle Dempsey
- Experiencia